FACTSHEET: AbbVie’s Response to the Coronavirus

AbbVie’s statement:

As one of the first pharmaceutical companies to respond to the emerging coronavirus (COVID-19) crisis, in late January, AbbVie donated a supply of Kaletra/Aluvia (lopinavir/ritonavir) to the Chinese health authorities for use as an experimental treatment option.

We are committed to making a meaningful contribution to efforts to combat this global public health crisis and continue to address urgent supply needs in several countries impacted by the outbreak. Our company is also working closely with the World Health Organization (WHO) and global health authorities to respond to the needs of patients impacted by COVID-19. Specifically, we have taken action through the provision of Kaletra/Aluvia as an experimental option for treatment of COVID-19, and through coordination with WHO, US NIH, and our industry partners. Our company is also exploring a potential research collaboration with the Innovative Medicines Initiative (IMI), which is exploring multiple potential COVID-19 treatment options.

Frequently Asked Questions

What do we know about lopinavir/ritonavir and COVID-19?

Clinical studies are needed to determine if lopinavir/ritonavir alone or in combination with other antiviral medications can be safely used to treat patients with COVID-19. AbbVie is working closely with the WHO, the U.S. National Institutes of Health, the Chinese Center for Disease Control, select health authorities and public health experts to determine the effectiveness and safety of lopinavir/ritonavir for treatment of COVID-19.

Late last month, in response to the Chinese government’s urgent request for supply, we made a donation of Kaletra/Aluvia and the active compounds lopinavir and ritonavir for use as an experimental option for treatment and for testing the efficacy and safety of our product for COVID-19. We are partnering with the Chinese Health Authorities to support over 15 randomized clinical trials and four cohort studies that they have ongoing for lopinavir/ritonavir combinations tested against COVID-19.

Is AbbVie participating in any research collaborations to explore treatment options for COVID-19?

We are engaged in research partnerships or have initiated the process of collaborations with different health authorities, such as the Chinese CDC, WHO and the Innovative Medicines Initiative (IMI) to support the determination of whether the combination of lopinavir/ritonavir is effective and safe in patients with COVID-19 infections.
**How is AbbVie working with government agencies and NGOs focused on responding to the coronavirus?**

AbbVie is working closely with WHO, global health authorities and the U.S. government to respond to the needs of patients and governments impacted by COVID-19. We are committed to making a meaningful contribution to efforts to combat this global public health crisis. Specifically, we have taken action through the provision of Kaletra/Aluvia as an experimental option for treatment of COVID-19, and through coordination with WHO, US NIH, and our industry partners. Our company is also exploring a potential research collaboration with the Innovative Medicines Initiative (IMI), which is exploring multiple potential COVID-19 treatment options.

**Does AbbVie expect any disruption to its supply chain?**

As the number of COVID-19 cases continue to rise around the world, questions are being raised about the impact the it may have on the global supply of medicine. AbbVie continues to closely monitor manufacturing and supply chain resources around the world and we do not anticipate any disruption to our medicine supply for patients as a result of COVID-19.

**How is AbbVie thinking about the demand of Kaletra/Aluvia for the coronavirus vs the need that HIV patients have for this medicine? Will supply of Kaletra/Aluvia for HIV patients be impacted?**

Regarding Kaletra/Aluvia, our first priority is to ensure uninterrupted supply for HIV patients around the world.

**Are AbbVie scientists working on a COVID-19 vaccine or treatment other than Kaletra/Aluvia?**

We will continue to assist in the global fight against COVID-19 where we can, but we do not have active COVID-19 research programs in virology or vaccines.

**Is AbbVie taking measures to support its employees?**

Out of an abundance of caution and like many other global companies, AbbVie has implemented temporary travel restrictions and advisories on business travel to ensure the safety of our employees and others. We are offering support to our employees through our AbbVie Employee Assistance Fund’s Employee Relief Program.